1/31/2006

The FDA has granted fast-track review status for BioMarin's Phenoptin for phenylketonuria, an oral small molecule therapeutic currently in phase III development. The company's CEO said the decision reflects the FDA's recognition that PKU "is a serious disease and unmet medical need."

Related Summaries